Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Stopped The closure of the study is driven by the decision to redesign the study protocol for future studies.

Conditions

• Eosinophilic Esophagitis

Interventions

• DRUG: BT-11 low
• DRUG: BT-11 high
• DRUG: Placebo

Sponsor

NImmune Biopharma